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HIGHLIGHTS
 Bone marrow mononuclear cell pre-seeding of polycarbonate bisurea–based tissue-engineered heart valves has
detrimental effects on long-term performance and in situ remodeling and, therefore, should be avoided.
 Leaﬂet-speciﬁc analysis revealed pronounced remodeling differences with regard to cell inﬁltration, scaffold
resorption, and extracellular matrix deposition within the same valve explant.
 The heterogeneity in remodeling of polycarbonate bisurea–based tissue-engineered heart valves may have
important safety implications in terms of clinical translation.
 An in-depth understanding of the mechanobiological mechanisms involved in the in situ remodeling is required
to limit the risk of unpredictable (maladaptive) remodeling.
SUMMARY
This study showed that bone marrow mononuclear cell pre-seeding had detrimental effects on functionality
and in situ remodeling of bioresorbable bisurea-modiﬁed polycarbonate (PC-BU)-based tissue-engineered heart
valves (TEHVs) used as transcatheter pulmonary valve replacement in sheep. We also showed heterogeneous
valve and leaﬂet remodeling, which affects PC-BU TEHV safety, challenging their potential for clinical trans-
lation. We suggest that bone marrow mononuclear cell pre-seeding should not be used in combination with PC-
BU TEHVs. A better understanding of cell–scaffold interaction and in situ remodeling processes is needed to
improve transcatheter valve design and polymer absorption rates for a safe and clinically relevant translation of
this approach. (J Am Coll Cardiol Basic Trans Science 2020;5:15–31) © 2020 The Authors. Published by Elsevier
on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
T ranscatheter heart valve replacement (TVR)approaches were initially introduced to treatpatients considered ineligible or at too high
risk for surgical valve replacement (1). Currently,
TVR techniques are being extended successfully to
cohorts of lower risk patients (1–3). Valve prostheses
compatible with TVR techniques are, however, still
based on glutaraldehyde-ﬁxed xenogeneic materials
prone to calciﬁcation and degeneration, causing a
high incidence of re-operations (4). Thus, novel
TVR-compatible prostheses that remain functional
throughout the patient’s life are needed.
We recently proposed the use of bioresorbable
polymers for the development of “off-the-shelf”
available tissue-engineered heart valves (TEHVs) with
in situ remodeling potential (5). In situ tissue engi-
neering involves implanting a cell-free scaffold that
should promote host cell adhesion and inﬁltration,
and induce tissue formation by gradual substitution of
the bioresorbable prosthesis by a living, native-like
tissue (6). We previously showed that TEHVs based
on the bioresorbable polymer bisurea-modiﬁed poly-
carbonate (PC-BU) retained functionality for up to
1 year in sheep when surgically implanted in a
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pulmonary position (5). The implanted valves exhibi-
ted gradual host cell repopulation while the polymer
was partially replaced by newly synthetized extracel-
lular matrix (ECM). This approach is suited for clinical
translation due to the off-the-shelf availability of the
valves, low production cost, scalability, and reduced
logistical complexity. Recently, a pulmonary valve
conduit based on this concept showed acceptable
preclinical safety and performance as well as cell
inﬁltration and neo-tissue formation, with partial
degradation of the polymer over the 12 months’
follow-up (7); this conduit has advanced into a clinical
pilot trial in children (NCT02700100, NCT03022708,
and NCT03405636).
The in situ approach strongly relies, however, on the
regenerative cascade induced by the inﬂammatory
response that occurs after valve implantation (6,8). To
be able to control the host’s response, bone marrow
mononuclear cell (BMMNC) pre-seeding has been
validated on bioresorbable vascular grafts (BVGs) in
both preclinical (9,10) and clinical (11,12) settings.
BVGs pre-seeded with BMMNCs exhibited accelerated
cellular inﬁltration and better remodeling toward
native-like tissue architecture in a cytokine-mediated
process in various animal models (9,10,13). The cyto-
kine monocyte chemoattractant protein-1 (MCP-1),
which can be secreted by BMMNCs, has been shown to
inﬂuence macrophage inﬁltration and favor remodel-
ing toward a well-organized vascular tissue (10,13,14).
Based on these ﬁndings, we hypothesized that pre-
seeding PC-BU transcatheter TEHVs with BMMNCs
would lead to a favorable remodeling response similar
to the one observed in vascular grafts in small
(10,13,15) and large (9,16) animal models. In addition,
we previously showed that pre-seeding of BMMNC
onto biodegradable polymeric scaffolds (based on
polyglycolic acid) is feasible and compatible with
transcatheter pulmonary (17) and aortic (18–20) valve
replacement techniques.
To test this hypothesis, transcatheter TEHVs based
on the supramolecular polymer PC-BU were seeded
with BMMNCs within a one-step intervention (17–20)
and implanted as pulmonary TVR in a translational
sheep model for chronic in vivo evaluation. In addi-
tion to assessing the overall feasibility and in vivo
performance of such valves for up to 6 months,
nonseeded TEHVs from a previous report (5) (and
that were produced under the same conditions)
served as control in the current study. To investigate
the impact of BMMNC pre-seeding on valve remod-
eling, a multimodal explant analysis was performed,
including a novel and in-depth individual
leaﬂet evaluation for the explanted valves using
quantitative and semi-quantitative gene expression
and histological analyses.
METHODS
STUDY DESIGN. Within this study, 16 TEHVs were
manufactured by electrospinning using the supramo-
lecular polymer PC-BU (Supplemental Materials 1.1).
The resulting mesh was then sutured onto a nitinol
stent. In vitro TEHV functionality was conﬁrmed by
using a pulse duplicator system followed by a dura-
bility test (n ¼ 2) (Supplemental Materials 1.2).
After in vitro BMMNC characterization via ﬂow
cytometry (Supplemental Materials 1.3, Supplemental
Table 1), 8 TEHVs were pre-seeded with 1  106 cells/cm2
autologous BMMNCs (Supplemental Materials 1.3)
before pulmonary TVR in sheep (identiﬁed as
BM-TEHV_1 to BM-TEHV_8) (Supplemental Table 2).
The following time points were considered: 4 h
(n ¼ 2) to prove principal safety and feasibility, and
4 weeks (n ¼ 2) and 24 weeks (n ¼ 4) to assess valve
functionality and remodeling potential. Nonseeded
TEHVs (n ¼ 6; TEHV_1 to TEHV_6), which were from a
previous report (5) and that were produced under the
same conditions, served as a control group for this
study with identical time points: 4 h (n ¼ 1), 4 weeks
(n ¼ 2), and 24 weeks (n ¼ 3).
In vivo and ex vivo analyses were performed for all
pre-seeded and control explants to assess the differ-
ences in valve remodeling via quantitative and semi-
quantitative analyses (as described later).
IN VIVO STUDY IN SHEEP. Transcatheter pulmonary
va lve replacement . The study was approved
by the local ethics committee (Veterinäramt,
Gesundheitsdirektion, Kanton Zürich ZH_09_2014)
and was conducted in conformity with the EU Direc-
tive 2010/63/EU for animal experiments and the
Guide for the Care and Use of Laboratory Animals,
published by the National Institutes of Health (pub-
lication no. 8023). All animals received humane care.
Transapical transcatheter pulmonary valve
replacement was performed as previously described
(21) and detailed in Supplemental Materials 1.4. In
short, following a right-sided thoracotomy, the right
cardiac ventricle was exposed, the apex was punc-
tured, and a guidewire inserted. After crimping a
diameter of 28 mm to a diameter of 10 mm, the TEHV
was loaded into a custom-made, pressure-based de-
livery system (Carag AG, Baar, Switzerland) and
positioned into the pulmonary root under ﬂuoro-
scopic control.
In v ivo va lve funct iona l i ty assessment .
Transesophageal echocardiography (TEE; iE33W
SEE PAGE 32
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xMATRIX Ultrasound, Philips Healthcare, Amsterdam,
the Netherlands) was used post-operatively and at 4,
12, and 24 weeks’ follow-up to verify TEHV func-
tionality. Valve regurgitation was graded as none,
trivial, mild, moderate, or severe. Invasive catheter-
based pressure measurements were performed
before animal euthanasia in the right ventricular
outﬂow tract and pulmonary artery to assess the
presence of stenosis (n ¼ 8).
EXPLANT EVALUATION. At the end of the planned
follow-up periods (n ¼ 11) or in case of pre-term
experiment termination (n ¼ 3) (Supplemental
Table 2), the animals were euthanized. Following
gross explant evaluation, longitudinally cut repre-
sentative samples of every TEHV leaﬂet were ﬁxed in
4% formalin, embedded in parafﬁn, and sliced into 2-
to 5-mm sections for (immuno)histological and
immunoﬂuorescence analyses (Supplemental
Materials 1.5). Tissue samples of the explanted valve
leaﬂets were snap-frozen in liquid nitrogen and
stored at –80C for gene expression analysis of che-
moattractant, anti-inﬂammatory and pro-
inﬂammatory, calciﬁcation, and ECM-related genes
(Supplemental Materials 1.6, Supplemental Table 3).
Assessment of TEHV leaﬂet d imens ions . For each
leaﬂet of the valves explanted after 18 and 24 weeks
(Supplemental Table 2), valve thickness and leaﬂet
length were measured by using Pannoramic Viewer
software (3DHistech, Ltd., Budapest, Hungary). For
each leaﬂet, thickness measures were obtained from 3
distinct histological sections and in 4 locations per
section: lower wall, leaﬂet base, leaﬂet middle region
(leaﬂet mid), and leaﬂet tip. For each location, a total
of 12 measures were obtained. The results were then
compared versus the average scaffold thickness at the
time of implantation (406  41 mm; n ¼ 10).
Possible changes in leaﬂet length were measured
from the histological sections (n ¼ 3) of each leaﬂet by
calculating the difference in percentage between the
length of the visible polymeric scaffold in the leaﬂet,
shown as an approximation of the initial leaﬂet length
at implantation, and the actual leaﬂet length upon
remodeling. Changes in leaﬂet length were not
compared between the different leaﬂets.
Semiquant i tat ive eva luat ion of h is to logy . For
each leaﬂet of the valves explanted after 18 and
24 weeks (Supplemental Table 2), 2 independent ob-
servers performed a semi-quantitative evaluation of
the histology by grading different remodeling (neo-
intimal growth, scaffold remnants, elastogenesis,
calciﬁcations, and vascularization) and phenotype
(endothelial cells, contractile cells, interstitial cells,
and macrophages) characteristics of the explants
from 0 (no expression) to 5 (high expression). For
each valve leaﬂet, the semi-quantiﬁcation was per-
formed in 4 locations per section: lower wall, leaﬂet
base, leaﬂet middle region (leaﬂet mid), and leaﬂet
tip. The average value obtained from the 2 evaluators
was then reported for each leaﬂet location.
STATISTICAL ANALYSIS. Data in the text are repre-
sented as mean  SD, unless stated otherwise. Leaﬂet
thickness measures (n ¼ 12) were evaluated as
repeated measures 2-way analysis of variance, with
Greenhouse-Geisser sphericity correction followed by
Tukey post hoc tests to correct for testing of all pair-
wise comparisons. Differences between the leaﬂet
length measured for the neo-tissue (n¼ 3) and scaffold
(n ¼ 3) remnants were evaluated as repeated measures
2-way analysis of variance followed by the Sidák mul-
tiple comparison test to correct for testing of scaffold
length and neo-tissue length within the same leaﬂet.
Prism software version 8 (GraphPad Software, Inc, San
Diego, California) was used for the analyses.
RESULTS
TRANSCATHETER PULMONARY VALVE REPLACEMENT
PROCEDURE USING PC-BU TEHVs IN COMBINATIONWITH
BMMNC PRE-SEEDING. After valve manufacturing,
in vitro valve functionality tests were performed
(Supplemental Figures 1A to 1E, Supplemental
Materials 2.1) to determine leaﬂet mobility and
conﬁrm a lack of stenosis or regurgitation and evaluate
valve durability (Supplemental Table 5). BMMNCs
were characterized by ﬂow cytometry by using a 5-
marker panel. The results conﬁrmed consistent
phenotypic marker expression among the different
donors (n ¼ 5) (Supplemental Figures 1F to 1K,
Supplemental Materials 2.2). In addition, BMMNC
gene expression analysis showed high expression of
MCP-1 and CXCL12 (chemoattractants), interleukin
(IL)-6 (pro-inﬂammatory), and bone gamma-
carboxyglutamate (B-GLAP) and tumor necrosis fac-
tor-a (pro-calciﬁcation) (n ¼ 5) (Figure 1A).
After autologous BMMNC isolation, PC-BU TEHVs
were homogeneously seeded with the cells (pre-
seeded, n ¼ 8) (Figure 1B) or nonseeded (n ¼ 6),
crimped down to 10 mm in diameter and loaded into
the delivery capsule (Figure 1C). Valve deployment in
the pulmonary position, performed under ﬂuoros-
copy (Figure 1D), was successful for every valve
(n ¼ 14). In all animals, angiographic assessment
proved adequate valve positioning, fully excluding
the native pulmonary valve leaﬂets. The majority of
the animals (n ¼ 13) had a swift recovery and did not
exhibit perioperative complications or post-operative
mortality. However, 1 animal (BM-TEHV_8) was
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FIGURE 1 In Vivo Functionality of Transcatheter TEHV as Pulmonary Valve Replacement
Continued on the next page
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euthanized 48 h after implantation due to severe
chest bleeding. The cause of bleeding was the perfo-
ration of the pulmonary artery by the stent. This an-
imal was therefore excluded from further analysis.
Acute in v ivo performance . Acute functionality
was sufﬁcient for all animals during the 4-h follow-
up, with no stenosis and no central or paravalvular
leakage independent of the pre-seeding. The corre-
sponding explants showed intact, pliable leaﬂets
covered by a ﬁbrin deposit and an absence of
macroscopic damage related to the crimping proced-
ure (Figure 1E).
Immunoﬂuorescence imaging of these explants
revealed ﬁbrin deposition all over the leaﬂet. As ex-
pected, BMMNC pre-seeded valves exhibited a more
abundant presence of (clustered) cells and greater
expression of MCP-1 compared with the nonseeded
group (Supplemental Figure 2).
Chron ic in v ivo performance . At implantation and
after 4 weeks, the BM-TEHVs presented with sufﬁ-
cient valve functionality, without stenosis or regur-
gitation (Figure 1F). TEE-assessed mean and peak
transvalvular gradient ranges were low
(Supplemental Table 6). Two animals (BM-TEHV_6
and BM-TEHV_7) were euthanized pre-term after
18 weeks because TEE indicated worsening perfor-
mance over time, starting at 12 weeks’ post-
implantation, with moderate to severe regurgitation
but no signs of stenosis. BM-TEHV_5 showed good
early functionality, without stenosis and regurgita-
tion, and correct valve positioning up to the 12-week
follow-up. However, owing to valve migration into
the right ventricle, incorrect valve positioning and
paravalvular leakage were detected after 24 weeks
(Supplemental Figure 3).
All the animals receiving nonseeded PC-BU TEHVs
completed their designated follow-up. For these
valves, post-operative and 4-week follow-up TEE
showed functional valves in all animals (Figure 1G),
with normal leaﬂet movement and excellent coapta-
tion with no (n ¼ 4) or only trivial (n ¼ 1) regurgitation
and low transvalvular pressure gradients
(Supplemental Table 6). Two animals exhibited
excellent valve function with no regurgitation after
24 weeks, whereas 1 animal (TEHV_4) had mild to
moderate central regurgitation. Paravalvular leakage
and stenosis were not present.
GROSS EXPLANT EVALUATION. BMMNC pre-seeded
and nonseeded TEHVs explanted after 4 weeks
showed signs of stent integration with the pulmonary
artery with intact, pliable leaﬂets (Supplemental
Figures 4A and 4D). Remarkably, tissue overgrowth
with partial fusion of adjacent leaﬂets at commissure
points was evident in the explanted BM-TEHVs but
not in the nonseeded TEHVs.
The BM-TEHVs explanted pre-term after 18 weeks
(n ¼ 2) showed good stent integration with the native
pulmonary artery and pliable leaﬂets. In these ex-
plants, we observed fusion of the leaﬂets at the
commissures (Figure 2A, Supplemental Figure 4B),
which most likely caused the increasing regurgitation
over time (Figure 1F). After 24 weeks, BM-TEHV_5
exhibited poor integration and stiff, fragile leaﬂets
(Supplemental Figure 4C).
Nonseeded TEHVs explanted after 24 weeks
showed good stent integration with the surrounding
tissues and pliable leaﬂets (Supplemental Figure 4E).
Two valves presented with small holes (1 to 2 mm) in
the central part of the leaﬂets’ free edges but retained
good coaptation. TEHV_6 had an additional hole (0.7
to 1 cm) in the belly region of one leaﬂet, an artifact
caused by the catheter used for invasive pressure
measurement performed before euthanization, as
only trivial regurgitation was observed on TEE
throughout the observation period.
HISTOLOGICAL EVALUATION. Histological evalua-
tion of samples harvested after 4 weeks conﬁrmed
cellularization and neo-collagen formation mainly in
the lower wall region for both pre-seeded
(Supplemental Figures 5A and 5B) and nonseeded
valves (Supplemental Figures 5C and 5D). For both
pre-seeded and nonseeded valves, vimentin-positive
FIGURE 1 Continued
(A) Scatter plot (single events; mean  SD) representing the gene expression proﬁle of bone marrow mononuclear cells (n ¼ 5) before
seeding. Values are displayed as dCt and normalized on the average expression levels of the housekeeping genes (glyceraldehyde
3-phosphate dehydrogenase and b-actin). (B) Top and bottom view of the bone marrow mononuclear cell pre-seeded tissue-engineered heart
valve (TEHV). (C) Representative image of the crimped valve loaded into the delivery capsule. (D) Movie stills of valve deployment in
pulmonary position performed under ﬂuoroscopy. (E) Bottom view of the explanted TEHV after 4 h in vivo. (F) Representative trans-
esophageal echocardiography images for BM-TEHV_6 exhibit sufﬁcient early valve functionality with progressive worsening leading to
moderate regurgitation at 12 weeks and pre-term animal euthanasia at 18 weeks. (G) Representative transesophageal echocardiography
images for TEHV_5 (control valve, as reported previously in Kluin et al. [5]) show sustained functionality at every time point. B-GLAP ¼ bone
gamma-carboxyglutamate; BMP ¼ bone morphogenetic protein; CXCL12 ¼ C-X-C Motif Chemokine Ligand 12; dCt ¼ difference between the
gene cycle threshold and the housekeeping gene cycle threshold; IL ¼ interleukin; MCP ¼ monocyte chemoattractant protein;
TGF ¼ transforming growth factor; TNF ¼ tumor necrosis factor.
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FIGURE 2 Macroscopic Appearance and Histological Analyses of Longitudinal Transection of BM-TEHV_6 Explant After 18 Weeks
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host cells were detected at the interface between the
pannus and the scaffold material. Early signs of
scaffold degradation were observed in the lower wall
and hinge regions and were associated with tissue
thickening and a-smooth muscle actin (SMA)-positive
and vimentin-positive cells. CD31-positive cells were
sparse and endothelialization incomplete at 4 weeks.
Early signs of calciﬁcation were detected in the BM-
TEHV_3 explant, with intracellular calcium deposits
in the lower wall, hinge region, and at the base of the
leaﬂet (Supplemental Figures 6A and 6B) but not on
the nonseeded valves.
The BM-TEHVs explanted pre-term after 18 weeks
(n ¼ 2) and the nonseeded TEHVs harvested after
24 weeks (n ¼ 3) exhibited neo-tissue formation with
thickening of the lower wall and hinge region, pres-
ence of elastic ﬁbers, and progressed scaffold reab-
sorption (including macrophages and giant cells)
(Figures 2B and 2C, Supplemental Figures 7A and 7B).
In addition, the lower wall region was highly vascu-
larized (Supplemental Figure 8). In both study
groups, the leaﬂet tip was fully repopulated by cells
and usually characterized by little collagenous tissue,
mostly within the polymeric scaffold ﬁbers. In few
explants (2 leaﬂets of 9, for both the pre-seeded and
nonseeded groups), leaﬂet tip encapsulation leading
to shortening was observed. For both pre-seeded and
nonseeded TEHVs, aSMA-positive cells were abun-
dant in the hinge and leaﬂet regions, whereas
vimentin-expressing cells were mostly present in the
lower wall and hinge region. Complete endotheliali-
zation, identiﬁed by the continuous monolayer of
CD31-positive cells, was detected in few of the non-
seeded valve leaﬂets (i.e., TEHV_4 and TEHV_6)
(Supplemental Figure 9). However, the majority of
the valve leaﬂets showed spot-dependent endothelial
cell coverage (i.e., good CD31-positive cell coverage
on the ﬁbrosa side of the hinge region; absence of
endothelial coverage toward the tip) (Figure 2C,
Supplemental Figure 7B). BM-TEHV_5, however,
showed a lack of collagen deposition on the scaffold,
which was in line with poor stent integration and
with over-time migration of the implant into the
ventricle (Supplemental Figure 10). Macroscopic
calciﬁed nodules were detected in 4 of 9 leaﬂets of
the BM-TEHVs (Supplemental Figures 6C and 6D),
whereas macroscopic calcium deposits were not
observed in any of the nonseeded TEHVs.
GENE EXPRESSION PROFILE OF PRE-SEEDED AND
NONSEEDED TEHVs. The gene expression proﬁle of
the 3 leaﬂets of each valve was evaluated via
reverse transcription quantitative polymerase chain
reaction (Figure 3). The heatmap shows differences
between the pre-seeded and nonseeded valves, with
a higher expression of chemoattractant (CXCL12),
pro-inﬂammatory (transforming growth factor [TGF]-
b1), pro-calciﬁcation (bone morphogenetic protein-2
and B-GLAP), and matrix remodeling (matrix metal-
loproteinase [MMP]-1 and MMP-9) genes in the BM-
TEHVs explants compared with the nonseeded
valves. Intervalve and interleaﬂet variability was
observed as well, with differential gene expression
proﬁles between valves of the same group (e.g., IL-4
expression in pre-seeded valves, IL-10 expression in
nonseeded valves) and between leaﬂets of the same
valve (e.g., TGF-b1 and IL-10 in TEHV_4; IL-4 in
BM-TEHV_5).
ASSESSMENT OF DIFFERENTIAL LEAFLET REMODELING
WITHIN THE SAME VALVE EXPLANT. PC-BU TEHVs
remodeling, evaluated via immunohistochemistry
and summarized in Figure 4, proved to be animal-
and leaﬂet-speciﬁc, independent of BMMNC pre-
seeding (Figure 5, Supplemental Figures 9A, 10,
11A, and 12A). Figure 5A shows TEHV_5, which pre-
sented similar remodeling of all 3 leaﬂets, with
comparable thickening and ECM deposition, poly-
mer reabsorption in the hinge region, and uncov-
ered leaﬂet tips (Figure 5A). Conversely, TEHV_6
showed a completely different remodeling of each
of the 3 leaﬂets: leaﬂet 1 presented minimal ECM
deposition in the lower wall, with no tissue forma-
tion in the leaﬂet; leaﬂet 2 underwent more sub-
stantial remodeling with thickening of the hinge
region and encapsulation of the leaﬂet tip; and
leaﬂet 3 showed advanced polymer degradation
combined with thickening of the leaﬂet base
(Figure 5B). Differential leaﬂet remodeling was also
observed in the gene expression proﬁle of each
single leaﬂet harvested from pre-seeded or non-
seeded TEHVs (Figure 3) and in the leaﬂet thickness
(Figure 6) and length (Figure 7).
FIGURE 2 Continued
(A) View of the top, bottom, and longitudinally dissected valve explant. Arrows indicate tissue overgrowth, and triangles point to leaﬂet fusion at the
commissures. (B) Tile scan of the elastica Van Gieson staining shows de novo collagen deposition in particular in the lower wall and hinge regions. A
calciﬁed nodule is marked by an asterisk. Little extracellular matrix is present on the leaﬂet. (C) Details of the remodeling process in the lower wall, hinge,
and 2 different leaﬂet regions (identiﬁed by the insets in A) by means of different (immuno-)histological staining. Arrows indicate CD31-positive
endothelial cells; “v” indicates vascularization. H&E ¼ hematoxylin and eosin; SMA ¼ smooth muscle actin; Vim ¼ vimentin.
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Generally, thickening (thickness value >1,000 mm)
was observed in the lower wall and hinge areas of the
leaﬂets, whereas minimal tissue deposition was
observed toward the free edges. However, explant
thickness measured in different leaﬂet regions
proved to be signiﬁcantly different among leaﬂets of
the same valve (Figure 6). Effective neo-tissue leaﬂet
length (Supplemental Figure 11C) was compared with
that of the visible scaffold for each leaﬂet of the valve.
Due to leaﬂet encapsulation by neointimal tissue,
considerable leaﬂet shortening (>8%) was observed
on both nonseeded and pre-seeded valves (Figure 7).
Notably, valve BM-TEHV_6 showed leaﬂet shortening
caused by folding of the leaﬂet tip toward the ﬁbrosa
side and fusion with the underlying tissue
(Supplemental Figure 12).
DISCUSSION
Bioresorbable, fully synthetic polymeric TEHVs have
been suggested as an attractive concept for heart
valve replacement, incorporating the advantages of
using cell-free polymeric materials (i.e., tailored
structural and mechanical properties, scalability,
customized degradation proﬁle, reduced cost and
complexity). By relying on the principle of in situ
tissue engineering, which comprises the inﬁltration
of host cells and the replacement of the initial scaf-
fold with endogenous ECM, the ﬁnal goal of the
approach is to achieve a living valve replacement via
an inﬂammation-mediated process (6). The concept
may become even more valuable when combined
with TVR techniques, given the increasing applica-
tion of minimally invasive valve replacement pro-
cedures in clinical practice (1–3).
The current study tested the feasibility of inﬂu-
encing the initial host response by pre-seeding the
PC-BU TEHVs with autologous BMMNCs in a one-step
approach. The results were compared with non-
seeded TEHVs from a previous report (5), which
served as the control group for the current study.
Other than valve functionality, we comparatively
analyzed the remodeling of each valve leaﬂet by us-
ing both quantitative and qualitative assessments to
FIGURE 3 Heatmaps Representing the Gene Expression Proﬁle of Pre-Seeded and Nonseeded TEHVs Explanted After 18 or 24 Weeks
The gene expression proﬁle of each leaﬂet (L1, L2, and L3) of pre-seeded (n ¼ 3) or nonseeded (n ¼ 3) TEHVs is displayed in dCt and normalized on the average
expression level of the housekeeping genes (glyceraldehyde 3-phosphate dehydrogenase and b-actin). High expression levels are represented in dark green. The
different genes of interest are grouped in accordance with their function in valve remodeling. MMP ¼ matrix metalloproteinase; other abbreviations as in Figure 1.
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FIGURE 4 Semi-Quantitative Evaluation of BMMNC Pre-Seeded and Nonseeded TEHV Remodeling After 18 and 24 Weeks
Data are presented as color-coded expression of the 3 leaﬂets (1, 2, and 3) for different valve locations (lower wall, hinge, leaﬂet base, mid, and tip).
BMMNC ¼ bone marrow mononuclear cell; TEHV ¼ tissue-engineered heart valve.
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FIGURE 5 Gross Evaluation and Histological Analyses of the 3 Leaﬂets of TEHV_5 and TEHV_6 Explanted After 24 Weeks
(A) Tile scan of the elastica Van Gieson staining for the 3 leaﬂets of TEHV_5, showing similar remodeling outcome. Hematoxylin and eosin
staining for leaﬂet one was previously reported in Kluin et al. (5). (B) Tile scan of the elastica Van Gieson staining for the 3 leaﬂets of TEHV_6,
showing differential remodeling ranging from little (leaﬂet 2) to no (leaﬂet 1) neo-tissue formation, to thickening of the wall, hinge, and
leaﬂet base regions (leaﬂet 3).
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further gain insight into the remodeling processes of
these bioresorbable valves.
IMPACT OF BMMNC PRE-SEEDING ON TEHV
FUNCTIONALITY AND REMODELING. BMMNCs are
an accessible cell source already used in clinical set-
tings to pre-seed BVGs for the treatment of congenital
single-ventricle anomalies (11,12). The safety of using
such an autologous cell source in combination with
BVGs in pediatric cardiovascular surgery has thus
been established.
Next, pre-seeding of BMMNCs onto biodegradable
polyglycolic acid (PGA)-based scaffolds proved to be
feasible and compatible with transcatheter pulmo-
nary valve replacement in non-human primates (17)
and transcatheter aortic valve replacement in sheep
(18–20). In line with the current study, Weber et al.
(17) reported adequate valve functionality with mild
to moderate regurgitation and detected substantial
cellular inﬁltration and tissue remodeling, whereas
any macroscopic calciﬁcations were absent after
FIGURE 6 Quantitative Evaluation of Leaﬂet Thickness
Thickness quantiﬁcation for each of the 3 valve leaﬂets (1 to 3) in 4 different locations of the valve: lower wall (black), leaﬂet base (dark red),
leaﬂet mid-region (green), and leaﬂet tip (blue). The gray dotted line at 400 mm indicates the average value of scaffold thickness at im-
plantation. The cutoff for statistical signiﬁcance was considered to be p < 0.05 (*p < 0.05; **p < 0.01; ***p < 0.001).
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4 weeks in vivo (terminal time point of the
experiment).
Moreover, Emmert et al. (20) showed the principal
feasibility of a transcatheter TEHV implantation
combined with a one-step BMMNC pre-seeding
procedure also in the aortic circulation for up to
2 weeks in sheep. The long-term effects of BMMNC
pre-seeding onto such PGA-based valves have yet to
be elucidated.
Interestingly, the results presented in this study
suggest detrimental consequences of BMMNC on
long-term performance and tissue remodeling
when pre-seeded onto PC-BU valves. Here, BMMNC
isolation and phenotypic characterization were
FIGURE 7 Quantitative Evaluation of Leaﬂet Length
Neo-tissue (blue bars) and scaffold (gray bars) leaﬂet length quantiﬁcation for each of the 3 valve leaﬂets. The percentage value indicates
leaﬂet shortening, mainly caused by the in-folding of the leaﬂet due to the neointimal tissue. The cutoff for statistical signiﬁcance was
considered to be p < 0.05 (*p < 0.05; **p < 0.01; ***p < 0.001).
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comparable to what was previously reported
(17,18,20), with similar marker expression for CD45,
CD11b, CD31, CD34, and CD44 as reported by Emmert
et al. (20). However, the current study substantially
differs from the aforementioned investigations
(17,18,20) in terms of the following: 1) the valve ma-
terial and design (PC-BU valve obtained from a
tubular electrospun conduit vs. a poly-4-
hydroxybutyrate–coated PGA nonwoven mesh cut
and shaped into a valve construct); 2) follow-up
period (4 and 24 weeks vs. 2 or 4 weeks); and 3) the
animal model used (sheep vs non-human primates
used by Weber et al. [17]). Together, these differences
could have signiﬁcantly affected long-term outcomes
regarding valve performance after BMMNC pre-
seeding. Importantly, these data again highlight the
necessity of long-term in vivo studies when vali-
dating the safety and efﬁcacy of a speciﬁc type of
polymeric heart valve concept toward potential clin-
ical translation.
The current study therefore discourages the use of
BMMNC pre-seeding when combined with PC-BU
TEHVs because of the observed regurgitation and
maladaptive remodeling. Speciﬁcally, we observed
fusion of neighboring leaﬂets that ultimately resulted
in increasing valve insufﬁciency. At the tissue level,
calcium deposits developed into pathological calciﬁ-
cations within the hinge regions after 18 weeks.
Interestingly, nonseeded PC-BU TEHVs did not pre-
sent calciﬁed nodules, even at later time points (5).
This outcome suggests that the presence of calciﬁc
deposits observed here in the BM-TEHVs was induced
by the pre-seeding (22) and not by the material itself,
as observed in other studies using other supramo-
lecular polymers (7).
This hypothesis is also supported by the gene
expression analysis, in which the genes involved in the
activation of valve interstitial cells (TGF-b1 and IL-6),
in calciﬁcation (B-GLAP and bone morphogenetic
protein-2), and in matrix remodeling of regurgitant
and stenotic valves (MMP-3 and MMP-9) (23) were
more highly expressed in pre-seeded valves compared
with the nonseeded TEHVs. We hypothesize that
although the local release of MCP-1 proved to be
beneﬁcial for integration and remodeling of BVGs
(10,14), it may lead to undesired outcomes in heart
valve replacements because high levels of this cyto-
kine were found in the calciﬁed aortic valve sections
(24). The cellular mechanisms by which BMMNC pre-
seeding seems to inversely inﬂuence the remodeling
of vessels and valves remain to be elucidated. One
distinguishing factor may be the difference in hemo-
dynamic loading, as previous in vitro studies have
shown that the chemotactic effects of both pre-seeded
BM-derived mesenchymal stromal cells and MCP-1 on
monocyte-derived macrophages depend on hemody-
namic loading (25,26).
DIFFERENTIAL VALVE AND LEAFLET REMODELING.
Both the explanted pre-seeded and nonseeded TEHVs
displayed substantial variability in the remodeling
outcomes that were not only pre-seeding dependent
but also valve and leaﬂet dependent. The current
study provides, for the ﬁrst time, an in-depth over-
view of the remodeling of each valve leaﬂet by
using quantitative and semi-quantitative analyses.
Notably, signs of undesired leaﬂet remodeling (e.g.,
leaﬂet encapsulation and shortening, presence of
aSMA-positive cells) were observed in both
study groups.
Impact of valve posit ioning on tissue remodeling.
Native valves are subjected to leaﬂet-dependent he-
modynamic loading (27,28). Hence, the variability in
leaﬂet remodeling may have been inﬂuenced by the
nonphysiological orientation of the TEHV leaﬂets in
the native annulus. In the current study, trans-
catheter implantation of PC-BU TEHVs was entirely
based on imaging guidance during the intervention,
using a stent that did not include any system for
optimizing prosthesis alignment with the native
valve leaﬂets. It is therefore possible that the TEHV
leaﬂets have some degree of misalignment with the
native leaﬂets. This may have resulted in non-
physiological hemodynamic loading of the valve,
which represents a risk factor for undesired mal-
adaptive remodeling phenomena (29,30). Previous
studies have indeed shown how the hemodynamic
loading can inﬂuence different remodeling processes,
such as macrophage polarization (26,31) and elasto-
genesis (32). Therefore, controlling the hemodynamic
variables may be the key to obtaining durable TEHVs
with consistent remodeling potential.
Impact of va lve des ign on t i ssue remodel ing . We
have shown how valve design can affect the mechan-
ical loading on the leaﬂets and, therefore, affect valve
functionality and tissue remodeling (33,34). TEHVs
based on an in vitro grown tissue-engineered matrix
depleted of cells, with a computational modeling–
inspired geometry to prevent tissue compaction in a
radial direction (35), exhibited sustained valve func-
tionality for up to 1 year in sheep and physiological-
like leaﬂet remodeling (33). Within this study, we
solved the problem of leaﬂet shortening observed in
most of the previously reported TEHVs (25,36–38) by
controlling valve design. Valve design also dictates
the opening and closing motion of the leaﬂets.
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Compared with the design of surgical valves (5), the
transcatheter PC-BU TEHVs resulted in incongruent
in vitro leaﬂet motion under hemodynamic loading,
with a nonphysiological bending of the central part of
the leaﬂet, which most likely caused the formation of
the observed holes (Supplemental Figure 1C). This
result suggests that, by inﬂuencing leaﬂet motion,
valve design can signiﬁcantly affect tissue remodeling
and questions the long-term performance of these
transcatheter PC-BU TEHVs.
STUDY LIMITATIONS. For the in vitro valve charac-
terization, the durability assessment did not take into
account the remodeling potential of the prostheses,
therefore signiﬁcantly underestimating valve dura-
bility. For the animal study, a limited number of an-
imals for each time point and group were used,
thereby restraining the possibility of obtaining sig-
niﬁcant differences in the groups and affecting data
variability. Moreover, due to unforeseen pre-term
animal euthanization, not all animals reached the
desired follow-up of 24 weeks. Finally, complete
valve remodeling was not achieved, as conﬁrmed by
the abundant polymeric remnants of the original
implant still visible after 24 weeks. Hence, further
longer term in vivo experiments (i.e., $52 weeks) are
warranted and should be performed in future studies.
CONCLUSIONS
This study reports the detrimental effects associ-
ated with autologous BMMNC pre-seeding onto
PC-BU–based polymeric TEHVs used as transcatheter
pulmonary valve replacement in sheep. Remarkably,
opposing our hypothesis, the presented results
discourage the use of BMMNC pre-seeding onto PC-
BU TEHVs, simplifying the in situ heart valve tissue
engineering approach using bioresorbable polymeric
valves. In addition, we reported differential valve and
leaﬂet remodeling independent of BMMNC pre-
seeding. To date, it remains unclear whether these
results can be extended to other polymers (i.e., PGA),
but differences in valve remodeling were already
observed in other surgical supramolecular polymer-
based valves (5,7). Such heterogeneity may affect
the safety of these supramolecular TEHVs, chal-
lenging their potential clinical translation (39). We
therefore suggest the need to further investigate and
understand the in situ remodeling potential of these
transcatheter supramolecular TEHVs by gaining in-
depth knowledge of the biological remodeling
processes (e.g., by using in-silico and in-vitro models
[40], and by comprehensive sheep-speciﬁc histo-
pathological analysis [41]). In addition, ensuring
valve antithrombogenicity is fundamental to prevent
thrombotic and thromboembolic adverse events. In
the current study, and similarly to what was previ-
ously reported for surgically implanted PC-BU TEHVs
at 6 months’ follow-up (5), incomplete leaﬂet endo-
thelialization was observed in the majority of the
valve leaﬂets, with the presence of scaffold-exposed
areas (particularly toward the leaﬂet-free edge).
Finally, further research should focus on ensuring
leaﬂet alignment with the native valve, improving
valve design to control the hemodynamic loadings,
and tuning scaffold degradation in vivo until com-
plete reabsorption occurs. Only then will it be
possible to make this in situ TEHV approach safe and
clinically relevant.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The observed
heterogeneity in the remodeling capacity of these bioresorbable
elastomeric TEHVs may affect the predictability and reproduc-
ibility of the valve performance, calling into question their clin-
ical translatability.
TRANSLATIONAL OUTLOOK: First, considering the differ-
ential leaﬂet remodeling observed, an in-depth analysis of each
valve leaﬂet should be included in the guidelines (e.g., Interna-
tional Standards Organization norms) for assessing the remod-
eling of TEHV prostheses. Second, because the remodeling
processes associated with these TEHVs heavily depend upon the
restorative capacities of the host cells, a tailored-approach using
computational modeling tools and valve-on-a-chip technologies
should be considered for recipients with different regeneration
potentials (e.g., with co-morbidities, elderly subjects). Third,
novel comprehensive monitoring and surveillance strategies
should be developed for all patients who receive a TEHV. A
continuous clinical follow-up will be essential to detect early
signs of malfunction or failure. Finally, long-term data will be
needed to validate this supramolecular polymer-based concept
with particular regard to the risk of potential unpredictable
(maladaptive) remodeling upon complete polymer degradation,
which is not yet fully controllable or understood
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APPENDIX For an expanded Methods
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ﬁgures, please see the online version of this
paper.
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